Long-term safety and efficacy of recombinant activated factor VII (NovoSeven) in haemophilia patients with inhibitors: interim post marketing study analysis of 5 patient exposure years | Zendy

AI Assistant Blog Pricing

Long-term safety and efficacy of recombinant activated factor VII (NovoSeven) in haemophilia patients with inhibitors: interim post marketing study analysis of 5 patient exposure years

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.